BioLife Solutions Inc
$ 25.83
1.25%
04 Dec - close price
- Market Cap 1,243,664,000 USD
- Current Price $ 25.83
- High / Low $ 25.87 / 24.68
- Stock P/E N/A
- Book Value 7.38
- EPS -0.38
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.05 %
- 52 Week High 29.62
- 52 Week Low 19.10
About
BioLife Solutions, Inc. is a premier provider of bioproduction tools and services that are pivotal for the gene and cell therapy industries, headquartered in Bothell, Washington. The company focuses on developing innovative solutions to optimize the preservation and processing of biological materials, which play a crucial role in the progression of life-saving therapies. With a steadfast emphasis on quality and reliability, BioLife Solutions is strategically positioned to leverage the escalating demand for advanced bioproduction technologies within the rapidly evolving biopharmaceutical sector.
Analyst Target Price
$32.10
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-08 | 2023-05-10 | 2023-03-16 |
| Reported EPS | 0.042 | -0.33 | 0.0355 | -0.016 | -0.0175 | -0.5 | -0.23 | -0.3 | -0.3 | -0.23 | -0.32 | -1.15 |
| Estimated EPS | -0.0113 | -0.03 | -0.035 | -0.0567 | -0.09 | -0.14 | -0.28 | -0.34 | -0.37 | -0.2 | -0.21 | -0.17 |
| Surprise | 0.0533 | -0.3 | 0.0705 | 0.0407 | 0.0725 | -0.36 | 0.05 | 0.04 | 0.07 | -0.03 | -0.11 | -0.98 |
| Surprise Percentage | 471.6814% | -1000% | 201.4286% | 71.7813% | 80.5556% | -257.1429% | 17.8571% | 11.7647% | 18.9189% | -15% | -52.381% | -576.4706% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.0038 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BLFS
2025-11-20 08:04:00
BioLife Solutions, Inc. announced the opening of the Aby J. Mathew Center for Biopreservation Excellence, a new conference and laboratory facility in Bothell, Washington. Named after founding team member Dr. Aby J. Mathew, the center will serve as a hub for research, training, and collaboration to advance biopreservation and cell processing innovation within the cell and gene therapy market. It will showcase BioLife's product portfolio, support process development with customers, and conduct internal research to develop next-generation cryopreservation products.
2025-11-20 08:04:00
BioLife Solutions (NASDAQ: BLFS) has opened the 4,500 square foot Aby J. Mathew Center for Biopreservation Excellence at its expanded Bothell headquarters. This state-of-the-art facility will showcase the company's cell processing product portfolio, provide training and workshops, support internal research, and facilitate industry collaboration in biopreservation. The center is also dedicated to developing next-generation cryopreservation products incorporating BioLife's proprietary ice recrystallization inhibitor (IRI) technology.
2025-11-18 20:52:30
Campbell & CO Investment Adviser LLC has acquired 13,256 shares of BioLife Solutions, Inc. (NASDAQ:BLFS) in Q2, valued at approximately $286,000, marking a new position for the firm. Institutional investors now own 93.24% of the company's stock, with other major firms like T. Rowe Price and Invesco also increasing their stakes. Despite recent insider selling, analysts maintain a "Moderate Buy" consensus rating with an average target price of $31.20 for BioLife Solutions.
2025-11-17 20:52:30
BioLife Solutions Inc. released an investor presentation on November 17, 2025, detailing its financial and operational strategies. The presentation highlighted a FY 2025 revenue guidance of $95-96 million, with an expected organic revenue growth of 27-29%, and a Q3 YTD 2025 adjusted EBITDA margin of 25%. BioLife's products are critical in the cell-based therapy market, specified in over 950 active global trials and used in approximately 90% of US-approved cell-based therapies.
2025-11-17 07:15:00
BioLife Solutions, Inc. announced its participation in several investor conferences during November and December 2025, including the Raymond James Napa Small Cap Symposium, Stephens Annual Investment Conference, Jefferies Global Healthcare Conference, Furey Research Partners Hidden Gems Conference, Wolfe Research Small & Mid-Cap Conference, and Northland Growth Conference. The company will be represented by its management team at these events. Their updated investor presentation is also available on their website.
2025-11-17 07:15:00
BioLife Solutions (NASDAQ: BLFS) announced its participation in multiple investor conferences throughout November and December 2025, including events hosted by Raymond James, Stephens, Jefferies, Furey Research Partners, Wolfe Research, and Northland Growth. The company also stated that its updated investor presentation is now available on the Investor Relations section of its website. These engagements aim to provide investors with insights into BioLife Solutions' bioproduction products and services for the cell and gene therapy market.
